CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D
This article was originally published in RPM Report
Executive Summary
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.